Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -2.77777777778 | 3.6 | 3.72 | 3.46 | 1758533 | 3.57592974 | DR |
| 4 | -1.76 | -33.4600760456 | 5.26 | 5.29 | 3.46 | 1057365 | 3.85079144 | DR |
| 12 | -1.79 | -33.8374291115 | 5.29 | 6.06 | 3.46 | 577459 | 4.465474 | DR |
| 26 | -0.9 | -20.4545454545 | 4.4 | 7.29 | 3.46 | 500620 | 5.20297866 | DR |
| 52 | 0.31 | 9.71786833856 | 3.19 | 7.9825 | 2.8536 | 325006 | 5.04468602 | DR |
| 156 | -0.75 | -17.6470588235 | 4.25 | 7.9825 | 1.53 | 137269 | 4.6176526 | DR |
| 260 | -10.4 | -74.8201438849 | 13.9 | 15.78 | 1.53 | 96929 | 4.91945158 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.